Amylyx Reports Third-Quarter 2026 Financial Results
Amylyx also reported positive topline results from its Phase 3 LUCIDITY trial of avexitide; the body text is truncated.
Story updates
12:06:47 PM UTC
SquawkNews
Amylyx reported a third-quarter 2026 net loss of $45.5 million, or $0.38 per share, and ended September with $768.1 million in cash, cash equivalents and marketable securities. The company reported positive topline results from its Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia…
12:13:52 PM UTC
SquawkNews
Amylyx Pharmaceuticals reported no product revenue in the third quarter, while its net loss widened year over year. Higher research and development spending, driven primarily by the Phase 3 LUCIDITY trial and other avexitide costs, and increased commercial-readiness and personnel expenses were part…